> Pollution cleanup for the Olympics is causing shortages of bulk raw materials for drugs, Indian pharmaceuticals firms say. Report
> Biogen and Elan--along with proponents of preemption--were dealt a setback as a federal judge declined to transfer a case from Massachusetts to a federal court in Iowa. Report
> Noven Pharmaceuticals said some Daytrana patches are being recalled some because some people could have difficulty removing the release liner of the patch before applying it to the skin. Report
> GlaxoSmithKline announced that a review of data from more than 14,600 patients in 54 clinical studies showed no increased risk of heart attack associated with the anti-HIV medication abacavir. Report
> Generic drug developer Par Pharmaceutical slashed its full-year profit outlook late Thursday as competition intensifies and sales decline. Report
> JP Morgan cut its rating on Novartis stock to "neutral" after a 14 percent increase in share price since June. Report
> Warner Chilcott's net income climbed to $33.6 million, or 13 cents a share, from $7.9 million, or 3 cents a share, as revenue rose 3 percent to $234 million. Report
> Four British hospitals and University College London have forged a £2 billion partnership that will create what's being billed as the largest biomedical research group in Europe. Report
> Shares of Spain's Zeltia shot up on the news that it has positive late-stage data for the ovarian cancer drug Yondelis to support its application for marketing approval. Report
> It happens often in drug development: a drug is expected to sail through the approval process, but the FDA delivers a not-approvable letter. However, only the drug developer ever sees the letter detailing why their drug has been rejected. That's because the FDA is still required by law to keep information on unapproved therapies secret, leading some to suggest that the agency needs to be more transparent. Report
And Finally... The U.K. has concluded that pandemic flu--not terrorism--is the most serious risk to its citizens. Report